A First in Human Study to Assess Safety, Tolerability and Pharmacokinetics of a Single Dose of REGN22044 in Healthy Adults

This clinical study will evaluate the study drug, REGN22044, in healthy participants. REGN22044 has not previously been studied in humans. The purpose of this study is to learn: * What side effects may happen when REGN22044 is taken * How much of REGN22044 is in the blood at different times * Whether the body makes antibodies against REGN22044 (which could make the drug less effective or could lead to side effects)

NCT Number	NCT07526116
Lead Sponsor	Regeneron Pharmaceuticals
Conditions	Healthy Volunteer
Enrollment	64 participants
Start Date	2026-05-07
Primary Completion	2027-05-27 (estimated)
Study Completion	2027-05-27 (estimated)
Updated on ClinicalTrials.gov	2026-04-13